Sleep Medicine Reviews
Volume 8, Issue 5 , Pages 355-366 , October 2004

Pharmacotherapy for cataplexy

  • William C. Houghton

      Affiliations

    • Orphan Medical, Inc., Medical Affairs, 13911 Ridgedale Drive, Suite 250, Minnetonka, MN 55305, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-952-513-6900; fax: +1-952-541-9209
    • ,
  • Thomas E. Scammell

      Affiliations

    • Harvard Institutes of Medicine, Room 821, Beth Israel Deaconess Medical Center, 77 Ave. Louis Pasteur, Boston, MA 02115, USA
    • Tel.: +1-617-667-0833; fax: +1-617-667-0810.
    • ,
  • Michael Thorpy

      Affiliations

    • Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
    • Tel.: +1-718-920-4841; fax: +1-718-798-4352.

References 

  1. Shiromani PJ, Armstrong DM, Bruce G, Hersh LB, Groves PM, Gillin JC. Relation of pontine choline acetyltransferase immunoreactive neurons with cells which increase discharge during REM sleep. Brain Res Bull. 1987;18:447–455
  2. Maloney KJ, Mainville L, Jones BE. Differential c-Fos expression in cholinergic, monoaminergic, and GABAergic cell groups of the pontomesencephalic tegmentum after paradoxical sleep deprivation and recovery. J Neurosci. 1999;19:3057–3072
  3. Nitz D, Siegel J. GABA release in the dorsal raphe nucleus: role in the control of REM sleep. Am J Physiol. 1997;273(1 Pt 2):R451–R455
  4. Gervasoni D, Darracq L, Fort P, Souliere F, Chouvet G, Luppi PH. Electrophysiological evidence that noradrenergic neurons of the rat locus coeruleus are tonically inhibited by GABA during sleep. Eur J Neurosci. 1998;10:964–970
  5. Curtis DR, Hosli L, Johnston GA, Johnston IH. The hyperpolarization of spinal motoneurones by glycine and related amino acids. Exp Brain Res. 1968;5:235–258
  6. Morales FR, Engelhardt JK, Soja PJ, Pereda AE, Chase MH. Motoneuron properties during motor inhibition produced by microinjection of carbachol into the pontine reticular formation of the decerebrate cat. J Neurophysiol. 1987;57:1118–1129
  7. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Cessation of activity in red nucleus neurons during stimulation of the medial medulla in decerebrate rats. J Physiol. 2002;545(Pt 3):997–1006
  8. Wu MF, John J, Boehmer LN, Yao D, Nguyen GB, Siegel JM. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J Physiol. 2003;
  9. Simon-Arceo K, Ramirez-Salado I, Calvo JM. Long-lasting enhancement of rapid eye movement sleep and pontogeniculooccipital waves by vasoactive intestinal peptide microinjection into the amygdala temporal lobe. Sleep. 2003;26:259–264
  10. Gulyani S, Wu MF, Nienhuis R, John J, Siegel JM. Cataplexy-related neurons in the amygdala of the narcoleptic dog. Neuroscience. 2002;112:355–365
  11. Overeem S, Lammers GJ, van Dijk JG. Weak with laughter. Lancet. 1999;354:838
  12. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al.  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59:1553–1562
  13. Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS, et al.  Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol. 1999;415:145–159
  14. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al.  Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA. 1999;96:10911–10916
  15. Peever JH, Lai YY, Siegel JM. Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism. J Neurophysiol. 2003;89:2591–2600
  16. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52:27–78
  17. Guilleminault C, Mignot E, Aldrich M, Quera-Salva MA, Tiberge M, Partinen M. Prazosin contraindicated in patients with narcolepsy. Lancet. 1988;2:511
  18. Aldrich MS, Rogers AE. Exacerbation of human cataplexy by prazosin. Sleep. 1989;12:254–256
  19. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. Depression and anxiety disorders. In:  Hardman JG,  Limbirb LE editor. The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001;p. 447–459
  20. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst. 1960;21:704–706
  21. Hishikawa Y, Ida H, Nakai K, Kaneko Z. Treatment of narcolepsy with imipramine (Tofranil) and desmethylimipramine (Pertofran). J Neurol Sci. 1966;3:453–461
  22. Gross MD. A note on cataplexy treated with protriptyline. Dis Nerv Syst. 1969;30:418
  23. Schmidt HS, Clark RW, Hyman PR. Protriptyline: an effective agent in the treatment of the narcolepsy–cataplexy syndrome and hypersomnia. Am J Psychiatry. 1977;134:183–185
  24. Bourdillon JL. Treatment of narcolepsy. Br Med J. 1971;1:670
  25. Guilleminault C, Carskadon M, Dement WC. On the treatment of rapid eye movement narcolepsy. Arch Neurol. 1974;30:90–93
  26. Linnoila M, Simpson D, Skinner T. Characteristics of therapeutic response to imipramine in cataplectic men. Am J Psychiatry. 1980;137:237–238
  27. Guilleminault C, Wilson RA, Dement WC. A study on cataplexy. Arch Neurol. 1974;31:255–261
  28. Chen CN. The use of clomipramine as an REM sleep suppressant in narcolepsy. Postgrad Med J. 1980;56(Suppl 1):86–89
  29. Shapiro WR. Treatment of cataplexy with clomipramine. Arch Neurol. 1975;32:653–656
  30. Guilleminault C, Raynal D, Takahashi S, Carskadon M, Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand. 1976;54:71–87
  31. Bental E, Lavie P, Sharf B. Severe hypermotility during sleep in treatment of cataplexy with clomipramine. Isr J Med Sci. 1979;15:607–609
  32. Parkes JD, Schachter M. Clomipramine and clonazepam in cataplexy. Lancet. 1979;2:1085–1086
  33. Chen SY, Clift SJ, Dahlitz MJ, Dunn G, Parkes JD. Treatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramine. J Sleep Res. 1995;4:113–118
  34. USP Dispensing Information, Greenwood Village, CO:MICROMEDEX; 2002.
  35. Chen C-N. Sleep, depression and antidepressants. Br J Psychiatry. 1979;135:385–402
  36. Martinez-Rodriguez J, Iranzo A, Santamaria J, Genis D, Molins A, Silva Y, et al. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia. 2002;17:113–116
  37. Grözinger M, Härtter S, Hiemke C, Griese EU, Röschke J. Interaction of modafinil and clomipramine as comedication in a narcolepstic patient. Clin Neuropharmcol. 1998;21:127–129
  38. McDaniel KD. Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol. 1986;9:207–234
  39. Wyatt RJ, Fram DH, Buchbinder R, Snyder F. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med. 1971;285:987–991
  40. Roselaar SE, Langdon N, Lock CB, Jenner P, Parkes JD. Selegiline in narcolepsy. Sleep. 1987;10:491–495
  41. Hublin C, Partinen M, Heinonen EH, Puukka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology. 1994;44:2095–2101
  42. Mayer G, Meier-Ewert K, Hephata K. Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol. 1995;18:306–319
  43. Gernaat HB, Haffmans PM, Knegtering H, Birkenhager TK. Tranylcypromine in narcolepsy. Pharmacopsychiatry. 1995;28:98–100
  44. Hohagen F, Mayer G, Menche A, Riemann D, Volk S, Meier-Ewert KH, et al.  Treatment of narcolepsy–cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine—a pilot study. J Sleep Res. 1993;2:250–256
  45. In:  McEvoy GK editors. American Hospital Formulary Service Drug Information 2003. Bethesda: American Society of Health-System Pharmacists; 2003;
  46. Mendelsohn MJ. Monoamine oxidase inhibitors. In:  Ford DA,  Delaney KA,  Ling LJ,  Erickson T editor. Clinical toxicology. Philadelphia, PA: WB Saunders; 2001;p. 546–557
  47. Wing YK, Lee S, Chiu HF, Ho CK, Chen CN. A patient with coexisting narcolepsy and morbid jealousy showing favourable response to fluoxetine. Postgrad Med J. 1994;70:34–36
  48. Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry. 1980;43:171–174
  49. Godbout R, Montplaisir J. The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol. 1986;9:46–51
  50. Schrader H, Kayed K, Bendixen Markset AC, Treidene HE. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand. 1986;74:297–303
  51. Sandyk R. Efficacy of trazodone in narcolepsy. Eur Neurol. 1985;24:335–337
  52. Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology. 1994;44:707–709
  53. Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep. 1986;9:371–373
  54. Thirumalai SS, Shubin RA. The use of citalopram in resistant cataplexy. Sleep Med. 2000;1:313–316
  55. Smith M, Parkes JD, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res. 1996;5(Suppl 1):217
  56. Guilleminault C, Mancuso J, Salva MA, Hayes B, Mitler M, Poirier G, et al. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep. 1986;9(1 Pt 2):275–279
  57. Larrosa O, de la Llave Y, Bario S, Granizo JJ, Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep. 2001;24:282–285
  58. Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2003;4:1165–1174
  59. Krahn LE, Moore WR, Altschuler SI. Narcolepsy and obesity: remission of severe cataplexy with sibutramine. Sleep Med. 2001;2:63–65
  60. Tunnicliff G. Significance of γ-hydroxybutyric acid in the brain. Gen Pharmacol. 1992;23:1027–1034
  61. Maitre M. The γ-hydroxybutyrate signaling system in brain: organization and functional implications. Prog Neurobiol. 1997;51:337–361
  62. Mamelak M, Escriu JM, Stokan O. The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry. 1977;12:273–288
  63. Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/wake patterns in narcolepsy–cataplexy. Can J Neurol Sci. 1980;7:23–31
  64. Scharf M, Brown D, Woods M, Brown L, Hirschowitz J. The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry. 1985;46:222–225
  65. Scrima L, Hartman PG, Johnson FH, Hiller FC. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy–cataplexy: double blind subjective measures. Biol Psychiatry. 1989;26:331–343
  66. Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J. Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep. 1993;6:216–220
  67. Scrima L, Hartman PG, Johnson FH, Thomas EE, Hiller FC. The effects of γ-hydroxybutyrate on the sleep of narcolepsy patients: a double blind study. Sleep. 1990;13:479–490
  68. US Xyrem® Multicenter Study Group . A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25:42–49
  69. US Xyrem® Multicenter Study Group . The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol. 2003;41:131–135
  70. US Xyrem® Multicenter Study Group . A 12-month, open-label, multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26:31–35
  71. Product labeling. Xyrem® (sodium oxybate) oral solution. Orphan Medical, Inc.
  72. Black JE, Ristanovic R, Mamelak M, Montplaisir J. Effect of increasing doses of sodium oxybate on nocturnal oxygen saturation: preliminary findings. Sleep. 2002;25(Suppl):A474
  73. Ristanovic R, Black J, Mamelak M, Montplaisir J. Analysis of dose effects of sodium oxybate on noctural respiratory disturbances. Sleep. 2002;25(Suppl):A473
  74. Gibson KM, Hoffman GF, Hodson AK, Bottiglieri T, Jakobs C. 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn of GABA metabolism. Neuropediatrics. 1998;29:14–22
  75. Van Cauter E, Plat L, Scharf MB, Leproult R, Cespredes S, L'Hermite-Baleriaux M. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by γ-hydroxybutyrate in normal young men. J Clin Invest. 1997;100:745–753
  76. Ristanovic R. decreased body-mass index (BMI) in narcolepstic patients treated with sodium oxybate. Sleep. 2003;26(Suppl):A87
  77. Kales A, Cadieux R, Soldatos CR, Tan TL. Successful treatment of narcolepsy with propranolol: a case report. Arch Neurol. 1979;36:650–651
  78. Kales A, Soldatos CR, Cadieux R, Bixler EO, Tan TL, Scharf MB. Propranolol in the treatment of narcolepsy. Ann Intern Med. 1979;91:741–743
  79. Meier-Ewert K, Matsubayashi K, Benter L. Propranolol: long-term treatment in narcolepsy–cataplexy. Sleep. 1985;8:95–104
  80. Paulus W, Homberg V, Noth J. Cataplexy relieved by tiapride. Arch Neurol. 1983;40:828
  81. Benbadis SR. Effective treatment of narcolepsy with codeine in a patient receiving hemodialysis. Pharmacotherapy. 1996;16:463–465
  82. Vaughn BV, D'Cruz OF. Carbamazepine as a treatment for cataplexy. Sleep. 1996;19:101–103
  83. Guilleminault C, Aftab FA, Karadeniz D, Philip P, Leger D. Problems associated with switch to modafinil—a novel alerting agent in narcolepsy. Eur J Neurol. 2000;7:381–384
  84. Parkes JD, Schachter M. Mazindol in the treatment of narcolepsy. Acta Neurol Scand. 1979;60:250–254
  85. Iijima S, Sugita Y, Teshima Y, Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep. 1986;9(1 Pt 2):265–268
  86. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:695–700
  87. Daniels E, King MA, Smith IE, Shneerson JM. Health-related quality of life in narcolepsy. J Sleep Res. 2001;10:75–81
  88. Littner M, Johnson SF, McCall WV, Anderson WM, Davila D, et al.  Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep. 2001;24:451–466
  89. Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med. 2001;2:5–17
  90. Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF. The Xyrem® Risk Management Program. Drug Safety. 2004; in press

☆ Dr. Houghton is an employee of Orphan Medical Inc, manufacturers of sodium oxybate. Dr. Scammell has received honoraria and grant support from Orphan Medical Inc. Dr Thorpy is on the Speakers Bureau for Orphan Medical Inc and Cephalon

PII: S1087-0792(04)00006-1

doi: 10.1016/j.smrv.2004.01.004

Sleep Medicine Reviews
Volume 8, Issue 5 , Pages 355-366 , October 2004

Article Tools

* Image Usage & Resolution